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ABSTRACT
Multiple sclerosis (MS) is a chronic,
autoimmune, inflammatory, demyelinating
disease of the central nervous system. MS is
increasingly recognized in the pediatric
population, and it is usually diagnosed around
15 years of age. The exact etiology of MS is still
not known, although autoimmune, genetic, and
environmental factors play important roles in its
development, making it a multifactorial disease.
The disease in children almost always presents in
the relapsing-remittent form. The therapy
involves treatment of relapses, and
immunomodulatory and symptomatic
treatment. The treatment of children with MS
has to bemultidisciplinary and include pediatric
neurologists, ophthalmologists, psychologists,
physiotherapists, and if necessary, pediatric
psychiatrists and pharmacologists. The basis of
MS therapy should rely on drugs that are able to
modify the course of the disease, i.e.
immunomodulatory drugs. These drugs can be
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subdivided into two general categories: first-line
immunomodulatory therapy (interferon
beta-1a, interferon beta-1b, glatiramer acetate)
and second-line immunomodulatory therapy
(natalizumab, mitoxantrone, fingolimod,
teriflunomide, azathioprine, rituximab,
dimethyl fumarate, daclizumab). Treatment of
relapses involves the use of high intravenous
doses of corticosteroids, administration of
intravenous immunoglobulins, and
plasmapheresis. We summarize here the current
available information related to the etiology and
treatment options inMS. Early administration of
immunomodulatory therapy is beneficial in
adults, while more studies are needed to prove
their effectiveness in pediatric populations.
Therefore, pediatric MS still represents a great
challenge for both, the early and correct
diagnosis, as well as its treatment.
Keywords: Etiology; Immunomodulatory
therapy; Multiple sclerosis; Pediatrics;
Treatment
INTRODUCTION
Multiple sclerosis (MS) is a chronic,
autoimmune, inflammatory, demyelinating
disease of the central nervous system [1]. The
disease most often begins between the second
and fourth decade of life, but it can also begin
later, as well as in childhood. In recent years,
MS is increasingly recognized in the pediatric
population [2], in which clinical findings,
magnetic resonance imaging (MRI), and
laboratory analyses may vary significantly as
compared to the adult population [3].
Therefore, new and emerging research in the
field of pediatric MS is of crucial importance for
both the early and correct diagnosis of pediatric
MS, as well as its treatment. The first clinical
and pathological description of MS was given by
Prof. Jean-Martin Charcot in the nineteenth
century, naming it sclerose en plaques [4]. A more
intensive study of the etiology and
pathophysiological processes underlying MS
began before World War II, when an
autoimmune theory was proposed, later
followed by the discovery of the genetic basis
of the disease [5–7]. The implementation of
immunomodulatory therapy took place in the
early nineties and it still is the first line of
treatment in MS patients [5].
One of the main characteristics of MS is its
geographic distribution [8], which is best
illustrated by the fact that 50 percent of all MS
patients are from Europe [9]. Results of different
studies indicate an increase in the number of
patients with MS since 1985, especially among
women [9], although this can be partially
explained by rapid advances in making the
diagnosis of MS during recent decades. The
assumption is that 2.3 million people in the
world have MS [10], while 2.7–10.5 % of all MS
cases represent patients younger than 18 years
of age [2]. Epidemiological studies indicate that
there are areas with a high prevalence of MS
([30/100,000) such as some northern Europe
countries and North America, and areas with a
low prevalence of MS (\5/100,000) such as
Africa, China, Japan, Latin and South America
[9, 11]. Sardinia is the place with the highest
prevalence of the pediatric MS in the world [12];
however, the area with the highest prevalence
of 300 per 100,000 is the Orkney Islands,
including both adult and pediatric MS [8]. If
we observe the American continent, MS is most
common in non-Hispanic white individuals.
Furthermore, in the last few years, pediatric MS
becomes more common in African Americans
than adult MS in the same population. African
Americans have more severe clinical
presentation compared to the white
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population if the disease starts early [13]. In the
United States, the prevalence varies from 58 to
95 per 100,000. In pediatric hospitals in
Canada, MS is increasingly diagnosed in
ethnic populations, such as Caribbean, Asian,
central and eastern European [14], more likely
caused by genetics, environmental factors,
infections, as well as inadequate exposure to
sunlight, and consequently vitamin D
deficiency. Namely, vitamin D deficiency or a
polymorphism of vitamin D receptor gene
diminishes its optimal function on the
immune system that consequently could lead
to increasing risk of MS [15]. However, its role in
development and modulating the course of MS
remains to be further elucidated.
Pediatric MS is usually diagnosed around
15 years of age [16], but one should be aware of
its incidence in even younger children. Early
onset of MS, i.e., in children who are below the
age of 10 years, has a frequency rate around
0.2–0.7 % [3], while the youngest patient
diagnosed with MS was only 2 years old [2]. The
sex ratiovariesdependingontheage,whichcould
indicate that sexhormonesplayan important role
in the pathogenesis of MS [17]. In early onset MS,
themale to female ratio is almost0.8–1. Following
the growth and the development of children, the
ratio increases to 1:2 after the age of 10 years [3]. A
positive family history has been shown in 6–20%
of children with MS [3].
ETIOLOGY
The exact etiology of MS is still not known,
although autoimmune, genetic, and
environmental factors play important roles in
its development, making it a multifactorial
disease [18]. Although more than 200 genes
may impact the occurrence of MS, the most
significant genetic factors contributing to the
development of MS are changes in the human
leukocyte antigen (HLA) DRB 1 gene [19]. In
addition to the genetic background, the
development of MS is also associated with
Epstein-Barr virus (EBV) infection [20], low
vitamin D levels [21], and smoking [22]. After
contact with infectious agents, the immune
system can activate autoreactive, circulating
cluster of differentiation 4? (CD4?) T
lymphocytes. These cells may later
differentiate into T helper (Th17) with the
help of interleukin 23 (IL-23), which regulates
the production of IL-17. The active cell can pass
through the blood–brain barrier (BBB) and
reacts with autoantigens, myelin antigens, or
oligodendrocytes through the mechanism of
molecular mimicry [23]. Th17 cells lead to the
inflammation within the central nervous
system (CNS), followed by migration of other
T cells through the BBB, and subsequent
activation of macrophages. The production of
pro-inflammatory cytokines during this
immunological response damages myelin and
oligodendrocytes, causing plaques of
inflammatory demyelination, a hallmark of
this disease [23, 24].
The course of MS is variable, but it represents
probably one of themost detailed descriptions of
all autoimmunedisorders, ranging fromabenign
type of MS (minimal disability after 15 years of
disease) to malignant forms of MS (severe
disability or death after a few months) [25]. The
various courses of MS are based on its clinical
characteristics. Clinical events that characterize
MS are relapse and/or progression. Relapses are
defined as the occurrence, recurrence, or
aggravation of neurological symptoms that last
more than 24 h and occur at least 30 days after a
previous attack. Between these relapses,
neurological status may normalize or there may
be still neurological sequelae [26]. Progression is
characterized by the continuous deterioration in
the past 6 months [27].
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The clinical symptoms of the first attack,
which last longer than 24 h and for which the
differential diagnosis is assumed to be
inflammatory demyelination with no evident
signs of encephalopathy, is called a clinically
isolated syndrome (CIS) [28]. According to some
studies, 30–75 % of patients with CIS will
progress to MS [29, 30]. The acquired
demyelinating syndromes in the pediatric
population were classified and defined in 2007
[31], and then updated in 2013 [26] by an
international consensus group. In addition to
CIS, a radiological isolated syndrome (RIS) was
described in recent years, which indicate MRI
changes that correspond to findings present in
demyelinating diseases, but these changes do
not correlate with clinical findings. According
to some studies, approximately 20 % of these
patients will develop MS within the next 5 years
[32]. The course of the disease leads to the
development of brain atrophy and thus, loss of
brain volume. In adults with MS, both global
and regional brain atrophy develops gradually
[33], as opposed to the pediatric MS, where most
commonly regional brain atrophy develops [34]
associated with cognitive and physical
disabilities [35]. The analysis of cerebrospinal
fluid in patients with pediatric MS can show
negative oligoclonal bands in the beginning of
the disease, but later they can be detected in
over 90 % of the cases [1]. The presence
oligoclonal bands increases the risk of MS, but
it is not exclusively specific for MS [1, 3].
The disease in children almost always
presents in the relapsing-remittent form (RR)
(85.7 % to even 100 % of cases) and the
majority of these patients fully recover from
the initial attack [2, 36]. Patients with RR MS,
despite the growth of the degree of disability,
are at no greater risk of a disease progression to
the secondary progressive form [37]. In the
pediatric population, the rate of recurrence in
the first 3 years of the disease is higher than in
adults [2]. Although the pediatric population
has a higher number of relapses compared to
adults, children also have faster recovery and
slower disease progression when compared to
adults [1]. The latest diagnostic techniques
allow identification of the disease even in very
young patients [38]. As in adults, patients in the
pediatric age must exhibit at least two clinical
demyelinating events, separated by at least
30 days, to be able to establish a diagnosis of
MS. It is also important to exclude all other
differential diagnostic causes which may
correspond to the clinical picture [1]. The
most common diseases that must be taken
into account before establishing a definitive
diagnosis of MS are presented in Fig. 1
[1, 39, 40].
One of the main characteristics, a must for
the diagnosis of MS, is the dissemination in
space and time [1]. The diagnosis of MS in the
pediatric population can be based on the
revised McDonald’s diagnostic criteria, but
these criteria are not recommended to use in
children younger than 12 years of age [1].
Consensus about the proposed definitions and
diagnostic criteria for pediatric multiple
sclerosis and related disorders was published
in 2007 [31] and was later updated in 2013
[26]. To meet the requirements for the
diagnosis, one should satisfy the following
criteria, according to Krupp et al. [26, 41],
Fig. 2.
Finally, the use of MRI as a diagnostic tool
has a high sensitivity in the detection of the
disease activity in both adults and in children.
At the beginning of the disease, children can
have multiple lesions on the MRI as compared
to adults, especially in the cerebellum and
brainstem [42]. Moreover, MRI findings are
often correlated with the clinical picture and
the degree of disability [17].
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TREATMENT OF PEDIATRIC MS
The therapy of pediatric MS involves treatment
of relapses, and immunomodulatory and
symptomatic treatment. The treatment of
children with MS has to be multidisciplinary
and has to include pediatric neurologists,
ophthalmologists, psychologists,
physiotherapists, and if necessary, pediatric
psychiatrist and pharmacologist. This article is
based on previously conducted studies and does
not involve any new studies of human or
animal subjects performed by any of the
authors.
Immunomodulatory Therapy
The basis of MS therapy should rely on drugs
that are able to modify the course of the disease,
i.e. immunomodulatory drugs. These drugs can
be subdivided into two general categories:
first-line immunomodulatory therapy and
second-line immunomodulatory therapy
(Table 1). According to the current
recommendations, pediatric patients with MS
should be treated with these disease-modifying
drugs, as early as possible [43].
First-Line Immunomodulatory Therapy
Drugs that modify the disease and can be given
to children older than 12 years are interferon
beta-1a (Avonex, Rebif), interferon beta-1b
(Betaferon), and glatiramer acetate
(Copaxone). These drugs have been approved
by the European Medicines Agency (EMA).
Avonex is given once a week in a dose of
30 lg i.m., while Rebif is administered three
times a week in a dose of 22–44 lg, s.c.
Interferon beta-1b is given every other day in
a dose of 250 lg s.c. and glatiramer acetate in a
dose of 20 mg also s.c. [44]. These drugs can
reduce the number of relapses in adults up to
30 % [2, 51]. Efficiency, effectiveness, and side
effects of these drugs are based on data from
clinical studies, but it is necessary to note that
some studies are still ongoing [2]. All of these
drugs have shown significant therapeutic
effectiveness by reducing the frequency and
severity of clinical relapses and disease activity
Fig. 1 Differential diagnosis of multiple sclerosis
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as shown by MRI of the brain, and are also able
to reduce the degree of disability [44]. These
drugs are well tolerated, but must be
administered i.m. or s.c., which can be a
problem for use in pediatric patients [2, 44, 51].
Interferon acts through specific receptors to
regulate signaling cascades. Its effect is
mediated through the inhibition of
autoreactive T cell inhibition of
pro-inflammatory cytokines, reduction of
lymphocyte migration, and induction of
anti-inflammatory mediators [2]. The most
common side effects are flu-like symptoms,
injection skin reaction, headache, myalgia,
nausea, fatigue, increased liver enzyme values,
and thyroid dysfunction [44]. In patients who
have developed flu-like symptoms, ibuprofen or
paracetamol can be used. The use of these drugs
requires monitoring of hematological
parameters and liver enzyme values each
month during the first 6 months and then
once every 3 months. Occasionally, it is also
bFig. 2 Diagnostic criteria for adult and pediatric MS
[magnetic resonance imaging (MRI), central nervous
system (CNS), acute disseminated encephalomyelitis
(ADEM), dissemination in space (DIS), dissemination in
time (DIT)]
Table 1 First-line and second-line immunomodulatory therapy (intramuscularly—i.m.; subcutaneously—s.c.;
intravenously—i.v.; per os—p.o.)
Dose Mode of
application
Dosing regimen References
First-line immunomodulatory therapy
Interferon
beta-1a
30 lg i.m. Once a week [43, 44]
22–44 lg s.c. Three times a
week
[43, 44]
Interferon
beta-1b
250 lg s.c. Every other day [44]
Glatiramer
acetate
20 mg s.c. Once a day [44]
Second-line immunomodulatory therapy
Natalizumab 3–5 mg/kg i.v. Once a month [2, 43, 45]
Mitoxantrone In a dose of 10–20 mg—up to a total dose of
200 mg
i.v. Once every
3 months
[46]
Fingolimod 0.5 mg p.o. Once a day [2]
Teriﬂunomide 7 and 14 mg p.o. Once a day [2]
Azathioprine 2.5–3 mg/kg p.o. Once a day [46]
Rituximab 500–1000 mg i.v. Every
6–12 months
[2, 46]
Dimethyl
fumarate
Initial dose 120 mg, therapeutic dose 240 mg p.o. Twice daily [47, 48]
Daclizumab 150 mg s.c. Once a month [49, 50]
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necessary to check thyroid function [52]. Based
on published data observed side effects of s.c.
administration of interferon beta-1a, in patients
who were older than 12 and even in patients
who were younger than 12 years, were:
injection-site reactions, influenza-like
symptoms, hepatic disorders, blood cell
disorders (e.g. thrombocytopenia, leucopenia,
anemia), elevations in alanine aminotransferase
and aspartate aminotransferase concentrations,
allergic reactions (e.g. rash, urticaria,
anaphylaxis), epilepsy and convulsive
disorders, thyroid dysfunction, autoimmune
diseases, bone/epiphyseal and cartilage
disorders, and serious infections [43].
Glatiramer acetate is relatively
well-tolerated, even during long-term use [44].
Glatiramer acetate achieves its effect by
inhibiting specific effector T-lymphocytes and
influencing antigen-presenting cells and
suppressor T-lymphocytes [2]. Some studies
suggest that glatiramer acetate may cause a
transient flushing-like reaction associated with
tachycardia [52]. Recent studies on the use of
glatiramer acetate in the pediatric population
are scarce.
Second-Line Immunomodulatory Therapy
Second-line drugs are available only as a part of
ongoing clinical studies. Natalizumab
(Tysabri) is a monoclonal antibody. The drug
targets a4b1-integrin and blocks migration of T-
and B-lymphocytes across the blood–brain
barrier [2]. It is given once a month by
intravenous infusion using a dose of 300 mg
[46] or 3–5 mg/kg [2]. Because of its high
efficacy, it is able to reduce the activity of MS
and its progression. Application of natalizumab
is contraindicated in the pediatric population;
however, according to some clinical trials,
natalizumab was able to significantly decrease
the disease activity and had fewer serious side
effects in pediatric patients as compared to
adults [53]. Although it reduces the number of
relapses by 68 % [46], this drug has a high risk of
serious side effects, such as progressive
multifocal leukoencephalopathy,
hypersensitivity, and infections [2, 53, 54].
Mitoxantrone (Novantrone) is
administered as an intravenous infusion once
every 3 months using a dose of 10–20 mg with a
maximal dose of 200 mg [46]. It is used in
patients with an aggressive form of disease or in
patients with severe cases of relapse remitting
MS and secondary progressive MS [55]. The
most common side effects of this drug are
cardiotoxicity, leukopenia, nausea, infections,
alopecia, fatigue, and amenorrhea [46, 55].
Fingolimod (Gylenia) tablets (0.5 mg) are
taken once daily orally which is a great
advantage over drugs that have to be
administered i.m or s.c.. The drug targets the
sphingosine-1-phosphate receptor [2]. It has
been used in adults since 2010, and its
application in pediatric patients is being tested
through clinical studies. Fingolimod has a
higher efficcacy than first-line drugs, but is
also associated with a risk of serious adverse
effects. The most common side effects include
abnormal heart rhythm after the first dose of
drug and macular edema [56].
Teriflunomide (Aubagio) has been accepted
as yet another drug that can be given orally.
Tablets of 7 and 14 mg are administered once a
day. Its safety profile is favorable and most
common unwanted effects are alopecia and
hepatotoxicity [2]. The results of the studies in
pediatric patients are yet to be expected in the
future.
Azathioprine is an immunosuppressive drug
used in adults. The drug antagonizes purine
metabolism and it is given orally in a dose of
2.5–3 mg/kg/day. The most common side
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effects are skin rashes, gastrointestinal
symptoms, cytopenia, and liver toxicity. There
is also a risk of cancer occurrence [46].
Cyclophosphamide (Cytoxan) is an
immunosuppressive drug with cytotoxic
effects. For the time being it is not given in
the pediatric population for this indication. The
most common side effects of this drug are
vomiting, amenorrhea, transient alopecia and
osteoporosis. Regular control in patients on
cyclophosphamide therapy is necessary in
order to prevent a possible development of
amenorrhea, sterility, infections and
malignancies [2, 46].
Rituximab (Rituxan) is chimeric
monoclonal immunoglobulin G1 (IgG1)—
kappa antibody that targets the CD20 receptor
on activated B lymphocytes. It has been shown
to reduce relapses in adolescents. A few cases of
progressive multifocal leukoencephalopathy
(PML) have been reported in patients with
systemic lupus erythematosus who were
treated with this drug, which represents a
serious and difficult side effect of this drug
[2, 46]. So far there are only few studies on the
use of rituximab in pediatric patients with MS,
which is why the recommendations for its
administration do not exist, and therefore
require further studies [57].
The mechanism of action of dimethyl
fumarate (Tecfidera) is still not fully known,
but the drug has been shown to reduce cytokine
production, lymphocyte count and result in
reduction of migratory activity of immune cells
through the BBB [58]. Monomethyl fumarate is
the active metabolite of this drug [59]. Dimethyl
fumarate is administered orally using a dose of
120 mg and 240 mg and is intended for the
treatment of patients with relapsing forms of
MS [47]. The most common and significant
side-effects of dimethyl fumarate are itching,
redness, nausea, vomiting, abdominal pain and
diarrhea, lymphopenia, PML, allergic reaction,
hives, rash, itching, hoarseness, and vision
problems.
Daclizumab (Zinbryta) is administeredonce a
month in a dose of 150 mg, s.c. Daclizumab is a
monoclonal humanized antibody that selectively
binds to the IL-2 receptor alpha-chain. The effect
of daclizumab showed a reduced relapse rate and
fewer new lesions on MRI [49, 50]. The most
common and significant side-effects of
daclizumab are serious infections,
gastrointestinal disorders, depression, liver
toxicity and elevations of liver enzymes, serious
cutaneous events. So far there is only one studyon
the use of daclizumab in pediatric patients with
MS. It reduces clinical and MRI disease activity in
pediatric patients. Side-effects were mild [49, 50].
Treatment of Relapses
Treatment of relapses involves the use of high
intravenous doses of corticosteroids such as the
administration of methylprednisolone in doses
of 20–30 mg/kg and up to 1000 mg per day once
a day in the morning. This treatment should
last 3–5 days and needs to be supported by
gastroprotective medications. Unlike in adults,
pediatric neurologists can decide if there is a
need for a short term extension of the
corticosteroid treatment [1]. The use of
corticosteroids this way reduces the number of
side-effects to a minimum. Side effects of
corticosteroid use in children are: mood
disorders, insomnia, hypertension, and
hyperglycemia [3]. If the administration of
corticosteroids does not result in improvement
of clinical findings, it can be replaced by a 5-day
administration of intravenous
immunoglobulins using a dose of 0.4 g/kg/day.
In addition, plasmapheresis is another
therapeutic option if the previous forms of
therapy did not result in satisfactory results [1].
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Treatment of Specific Symptoms
Symptomatic therapy should be directed
towards eliminating specific symptoms, which
may occur in the course of the disease. The most
common symptoms that occur in children are
pain, anxiety, depression, fatigue, stiffness
(spasm), interference with urination, and
sexual dysfunction. If the symptoms of anxiety
and depression are noticed, it is necessary to
immediately include a pediatric or adolescent
psychiatrist in order to prevent progression.
Pain that occurs in MS patients is of
neuropathic origin and should be treated
according to the recommendations for the
treatment of neuropathic pain (tricyclic
antidepressants, gabapentin and pregabalin,
5% lidocaine, and tramadol) [60].
CONCLUSION
Pediatric MS still represents a major diagnostic
and therapeutic problem. Early administration of
immunomodulatory therapy is beneficial in
adults, while more studies are needed to prove
their effectiveness in pediatric populations.
Therefore, better knowledge of both the etiology
and pathogenesis of pediatric MS is of great
importance in search of the correct treatment.
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